[ad_1]
US researchers said empagliflozin, a recently developed diabetes drug that can effectively treat heart failure in diabetics and non-diabetics, as the clinical study, published in the Journal of the American College of Cardiology, showed that this drug can improve the size and shape of the heart. And its function, which leads to improved exercise capacity and quality of life, which reduces hospitalization for patients with heart failure.
According to a newspaper article TIME NOW NEWS The study author said Carlos Santos “Promising results from our clinical trials show that this diabetes drug can improve the lives of heart failure patients with reduced ejection fraction, increase their exercise capacity and improve their quality of life with little or no side effects. ”
“Our study also identifies why this drug is so effective: because it improves heart function, which is not yet understood,” Santos Gallego said.“.
More importantly, the researchers noted that the drug does not appear to cause hypoglycemia or low blood sugar levels in patients with diabetes..
For the sake of the experiment, known as “EMPATROPISM” , The researchers recruited 84 chronic heart failure patients with reduced ejection fraction (EF) Left ventricular percentage pumps blood with each contraction and gives it treatment with Ambagelevlozin or placebo .
They all underwent basic assessments including a cardiac MRI, a cardiopulmonary exercise test on a bicycle wearing a face mask to test oxygen levels, a six-minute gait test, and quality of life questionnaires, patients received treatment or placebo for six months, with some brief safety visits.At one and three months at the end of six months, patients underwent the same tests.
Researchers found that nearly 80% of patients treated with the drug Ambagelevlozin showed marked improvement and their heart returned to near normal..
Their hearts have become smaller and less dilated due to less congestion and fluid buildup in the body, meaning their heart failure has become less severe and their heart walls thinner, the study also showed that patients who took empagliflozin had about a 10% improvement in their exercise levels, which is a statistically important difference from.
.
[ad_2]
Source link
